James P Ebben
Overview
Explore the profile of James P Ebben including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Solid C, Collins A, Ebben J, Chen S, Faravardeh A, Foley R, et al.
BMC Nephrol
. 2014 Feb;
15:30.
PMID: 24507475
Background: The choice of vascular access type is an important aspect of care for incident hemodialysis patients. However, data from the Centers for Medicare & Medicaid Services (CMS) Medical Evidence...
2.
Gilbertson D, Peng Y, Bradbury B, Ebben J, Collins A
Am J Nephrol
. 2009 Sep;
30(6):491-8.
PMID: 19786739
Background/aims: Hemoglobin level variability in hemodialysis patients is common, and has been associated with comorbidity, intercurrent illness, and mortality risk. We aimed to describe the influence of anemia management interventions...
3.
Gilbertson D, Ebben J, Foley R, Weinhandl E, Bradbury B, Collins A
Clin J Am Soc Nephrol
. 2007 Nov;
3(1):133-8.
PMID: 18045862
Background/objectives: Awareness of hemoglobin level variability in dialysis patients is increasing, as is interest in its potential implications. In this retrospective, national study of associations between the degree of hemoglobin...
4.
Ebben J, Gilbertson D, Foley R, Collins A
Clin J Am Soc Nephrol
. 2007 Aug;
1(6):1205-10.
PMID: 17699349
National payment policies target a hemoglobin range of 11 to 12.5 g/dl for patients with ESRD. However, clinical complications and provider practices may contribute to wide fluctuations over time. This...
5.
Collins A, Ebben J, Gilbertson D
Am J Kidney Dis
. 2006 Dec;
49(1):135-42.
PMID: 17185154
Background: This study investigates provider practices regarding recombinant human erythropoietin (rHuEPO) dose when patient hemoglobin levels exceeded National Kidney Foundation-Dialysis Outcomes Quality Initiative target levels and reached 13 g/dL or...
6.
Projecting the number of patients with end-stage renal disease in the United States to the year 2015
Gilbertson D, Liu J, Xue J, Louis T, Solid C, Ebben J, et al.
J Am Soc Nephrol
. 2005 Nov;
16(12):3736-41.
PMID: 16267160
The size of the prevalent ESRD population in the United States increased dramatically during the 1990s, from 196,000 in 1991 to 382,000 in 2000. Incidence also increased considerably during the...
7.
Fan Q, Liu J, Ebben J, Collins A
Am J Kidney Dis
. 2005 Sep;
46(4):661-8.
PMID: 16183421
Background: The impact of dialyzer reuse on the mortality of hemodialysis patients is debated. This study assesses reuse-associated mortality across US dialysis provider systems (for-profit, not-for-profit; hospital-based, and freestanding units)...
8.
St Peter W, Khan S, Ebben J, Pereira B, Collins A
Kidney Int
. 2004 Jun;
66(1):313-21.
PMID: 15200439
Background: The cost of care for end-stage renal disease (ESRD) is known to be high. The factors responsible for higher ESRD cost develop during chronic kidney disease (CKD), where the...
9.
Collins A, Liu J, Ebben J
Nephrol Dial Transplant
. 2004 Mar;
19(5):1245-51.
PMID: 14993497
Background: The reuse of haemodialysers has been practiced in the United States for >20 years. We investigated mortality and hospitalization risk according to various reuse practices, testing the hypothesis that...
10.
Xue J, Dahl D, Ebben J, Collins A
Am J Kidney Dis
. 2003 Oct;
42(5):1013-9.
PMID: 14582045
Background: Dialysis access is critical for therapy delivery. Few studies have linked type of dialysis access to patient survival in the elderly population. Methods: We included 1995 to 1997 incidence...